1041 related articles for article (PubMed ID: 29155348)
1. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
Teng F; Meng X; Kong L; Yu J
Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
3. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
4. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
5. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
Iivanainen S; Koivunen JP
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952311
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.
Qin BD; Jiao XD; Zang YS
Med Hypotheses; 2018 Jul; 116():111-113. PubMed ID: 29857892
[TBL] [Abstract][Full Text] [Related]
7. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
8. Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
Oncology (Williston Park); 2020 Aug; 34(8):321-327. PubMed ID: 32785929
[TBL] [Abstract][Full Text] [Related]
9. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
10. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
11. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
13. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
14. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
[TBL] [Abstract][Full Text] [Related]
16. Emerging biomarkers for PD-1 pathway cancer therapy.
Lim JS; Sundar R; Chénard-Poirier M; Lopez J; Yap TA
Biomark Med; 2017 Jan; 11(1):53-67. PubMed ID: 27936870
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Frelau A; Pracht M; Le Sourd S; Lespagnol A; Corre R; Ménard C; Tarte K; Mosser J; Edeline J
Bull Cancer; 2018 Dec; 105 Suppl 1():S80-S91. PubMed ID: 30595202
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
